George E. Woody

George E. Woody

Auto-generated profile, based on publicly available information

George E. Woody

Society of Alcoholism and Other Addictions, Vogur Hospital, Reykjavík, Iceland (VR, IH, TT, ME); Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Treatment Research Institute, Philadelphia, PA (GEW); and the National Institute on Drug Abuse, Rockville, MD (JK)

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2017 in Journal of Addiction Medicine
Verified
Journal Article
Closed access
VRValgerdur Runarsdottir
Valgerdur Runarsdottir
IHIngunn Hansdottir
Ingunn Hansdottir
TTThorarinn Tyrfingsson
Thorarinn Tyrfingsson
MEMagnus Ncac Einarsson
Magnus Ncac Einarsson
KDKaren Dugosh
Karen Dugosh
GWGeorge E. Woody
George E. Woody
Objective: Explore the efficacy of extended-release injectable naltrexone (XR-NTX) for preventing relapse to amphetamine use. Method: Clinical trial of 100 amphetamine-dependent, treatment-seeking patients who were randomized to 6 monthly 380 mg doses of XR-NTX or matching placebo before entering intensive outpatient after varying lengths of inpatient treatment in Reykjavik, Iceland. Weekly urine drug tests, retention, and standardized instruments assessed efficacy. Results: Of 169 approached, 100 were randomized. Although amphetamine dependence was the main reason for seeking treatment, three-quarters or more of participants had 1 or more other substance dependencies. Of 51 randomized to XR-NTX, 20 received 4 or more injections; of 49 assigned to placebo, 26 received 4 or more injections. Of the planned 2400 weekly urine drug tests, 1247 were collected (52%); 4% of these were positive for amphetamine, 8% for benzodiazepine, 7% for marijuana, 1% for cocaine, and 1% for opioid. XR-NTX had no effect on amphetamine-positive tests, retention, or other outcomes. Those providing half or more of their tests attended more weeks of treatment than those providing less than half of their tests (m = 10.76 vs 3.31; t (92) = 5.91, P < 0.0001), and 92 participants provided at least 1 test. Conclusions: Adding XR-NTX to the usual combination of inpatient and intensive outpatient treatment did not reduce amphetamine use. The low prevalence of substance use among collected urine samples, and the association between collected samples and weeks in treatment, was consistent with other studies showing that staying in treatment is associated with better outcomes.

1 March 2015 in Harvard Review of Psychiatry
Verified
Journal Article
Open access
RRRichard A. Rawson
Richard A. Rawson
GWGeorge Woody
George Woody
TKThomas Kresina
Thomas Kresina
SGSteven Gust
Steven Gust
Over the past decade, the amount and variety of addiction research around the world has increased substantially. Researchers in Australia, Canada, United Kingdom, United States, and western Europe have significantly contributed to knowledge about addiction and its treatment. However, the nature and context of substance use disorders and the populations using drugs are far more diverse than is reflected in studies done in Western cultures. To stimulate new research from a diverse set of cultural perspectives, the National Institute on Drug Abuse (NIDA) has promoted the development of addiction research capacity and skills around the world for over 25 years. This review will describe the programs NIDA has developed to sponsor international research and research fellows and will provide some examples of the work NIDA has supported. NIDA fellowships have allowed 496 individuals from 96 countries to be trained in addiction research. The United Arab Emirates and Saudi Arabia have recently developed funding to support addiction research to study, with advice from NIDA, the substance use disorder problems that affect their societies. Examples from Malaysia, Tanzania, Brazil, Russian Federation, Ukraine, Republic of Georgia, Iceland, China, and Vietnam are used to illustrate research being conducted with NIDA support. Health services research, collaboratively funded by the U.S. National Institutes of Health and Department of State, addresses a range of addiction service development questions in low- and middle-income countries. Findings have expanded the understanding of addiction and its treatment, and are enhancing the ability of practitioners and policy makers to address substance use disorders.

27 January 2017 in F1000Research
Verified
Journal Article
Open access
PDF file
GWGeorge E. Woody
George E. Woody
The development of medications for treating persons with opioid use disorders has expanded the number of evidence-based treatment options, particularly for persons with the most severe disorders. It has also improved outcomes compared to psychosocial treatment alone and expanded treatment availability by increasing the number of physicians involved in treatment and the settings where patients can be treated. The medications include methadone, buprenorphine, buprenorphine/naloxone, and extended-release injectable naltrexone. Studies have shown that they are most effective when used over an extended, but as-yet-unspecified, period of time and with counseling and other services, particularly for the many with psychosocial problems. Though controversial in some cultures, well-designed studies in Switzerland, the Netherlands, Germany, and Canada have demonstrated the efficacy of supervised heroin injecting for persons who responded poorly to other treatments, and this treatment option has been approved by Switzerland and a few other E.U. countries. The degree to which medication-assisted therapies are available is dependent on many variables, including national and local regulations, preferences of individual providers and their geographical location, treatment costs, and insurance policies. Greater availability of medication-assisted therapies has become a major focus in the U.S. and Canada, where there has been a marked increase in deaths associated with heroin and prescription opioid use. This paper provides a brief summary of these developments.

1 January 1990 in International Journal of the Addictions
Verified
Journal Article
Closed access
MAMarcia Anderson
Marcia Anderson
SCSandra B. Coleman
Sandra B. Coleman
WFWilliam Ford
William Ford
RGRichard L. Gorsuch
Richard L. Gorsuch
HKHoward Kaplan
Howard Kaplan
GWGeorge Woody
George Woody

6 January 2021
Verified
Report
Closed access
GWGeorge E. Woody
George E. Woody
SPSabrina Poole
Sabrina Poole
EYElmer Yu
Elmer Yu
KLKevin G. Lynch
Kevin G. Lynch
This research project is in progress. PCORI will post the research findings on this page within 90 days after the results are final.

1 July 2014 in Drug and Alcohol Dependence
Verified
Journal Article
Closed access
PDF file
WLW. Ling
W. Ling
MHMaureen P. Hillhouse
Maureen P. Hillhouse
CTC. Thomas
C. Thomas
AHA. Hasson
A. Hasson
JAJ. Annon
J. Annon
MDM.A. Dawes
M.A. Dawes